Cardiome Pharma Corp., of Vancouver, British Columbia, promoted Doug Janzen to president and chief business officer.

Cell BioSciences Inc., of Palo Alto, Calif., appointed Blaine Bowman to its board.

CellCentric, of Cambridge, UK, appointed Tim Fell chief operating officer.

Celtic Pharmaceutical Holdings LP, of New York, appointed Reinaldo Diaz managing director and partner.

CMC Biopharmaceuticals A/S, of Copenhagen, Denmark, appointed Diana Morgan chief business officer.

Codexis Inc., of Redwood City, Calif., appointed Peter Seufer-Wasserthal vice president and general manager, Codexis Enzymes and Intermediates. It also appointed Keith McKay U.S. director of sales and marketing for the enzymes and pharmaceutical intermediates business unit.

CytoDyn Inc., of Santa Fe, N.M., appointed Gregory Gould to its board.

Cytori Therapeutics Inc., of San Diego, appointed to its clinical advisory board David Cohen, Peter Fitzgerald, Martin Leon, Robb MacLellan, Emerson Perin, Richard Schatz, Patrick Serruys, James Udelson and Neil Weismann.

Dendreon Corp., of Seattle, named Christopher Lockett senior director of government affairs, and promoted Mark Frohlich to vice president of clinical affairs.

Duska Therapeutics Inc., of Bala Cynwyd, Pa., appointed Wayne Lorgus chief financial officer.

Encysive Pharmaceuticals Inc., of Houston, appointed Thierry Plouvier vice president, European operations.

Ensemble Discovery Corp., of Cambridge, Mass., appointed Laurence Reid chief business officer.

Genaera Corp., of Plymouth Meeting, Pa., appointed Peter Savino to its board, and Michael Gast senior vice president, clinical research and development.

Genesis Bioventures Inc., of New York, appointed Kaspar Baenziger to its corporate advisory board.

Helix BioMedix Inc., of Bothell, Wash., appointed Weston Anson and David O'Connor to its board.

Idexx Laboratories Inc., of Westbrook, Maine, appointed Barry Johnson to its board.

Infinity Pharmaceuticals Inc., of Cambridge, Mass., appointed Julian Adams president and chief scientific officer, Adelene Perkins executive vice president and chief business officer, and David Grayzel vice president, clinical development and medical affairs.